TY - JOUR
T1 - Dissecting the polygenic basis of atherosclerosis via disease-associated cell state signatures
AU - Örd, Tiit
AU - Lönnberg, Tapio
AU - Nurminen, Valtteri
AU - Ravindran, Aarthi
AU - Niskanen, Henri
AU - Kiema, Miika
AU - Õunap, Kadri
AU - Maria, Maleeha
AU - Moreau, Pierre R.
AU - Mishra, Pashupati P.
AU - Palani, Senthil
AU - Virta, Jenni
AU - Liljenbäck, Heidi
AU - Aavik, Einari
AU - Roivainen, Anne
AU - Ylä-Herttuala, Seppo
AU - Laakkonen, Johanna P.
AU - Lehtimäki, Terho
AU - Kaikkonen, Minna U.
N1 - Funding Information:
We acknowledge Single Cell Genomics Core, Genome Center and Cell and Tissue Imaging Unit at University of Eastern Finland, Finnish Functional Genomics Centre, and Biocenter Finland for infrastructure support. This research has been conducted with the UK Biobank Resource ( https://www.ukbiobank.ac.uk/ ) under application number 58990. We are grateful to Resolve Biosciences for their excellent service in optimizing and performing the Molecular Cartography experiments. This study was funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant no. 802825 to M.U.K.), Academy of Finland (grant no. 333021 and 335973 to M.U.K.; 311081 and 314557 to T. Lönnberg; 349708 to P.P.M.; 314556 and 335975 to A. Roivainen; 321535 and 328835 to J.P.L.), InFLAMES Flagship Programme of the Academy of Finland (337530 to T. Lönnberg), Finnish Foundation for Cardiovascular Research (M.U.K., P.R.M., and J.P.L.), Instrumentarium Science Foundation (P.R.M.), Ida Montinin Foundation (P.R.M.), Sigrid Jusélius Foundation (M.U.K.), GenomMed doctoral program (740264 to A. Ravindran), and Jane and Aatos Erkko Foundation (A. Roivainen). The Tampere Vascular Study (TVS) was supported with grants from the Competitive Research Funding of the Tampere University Hospital (grants 9M048 and 9N035 to T. Lehtimäki), the Emil Aaltonen Foundation (to T. Lehtimäki), the Pirkanmaa Regional Fund of the Finnish Cultural Foundation , the Research Foundation of Orion Corporation , the Jenny and Antti Wihuri Foundation , and the Academy of Finland (grants 322098 and 104821 ), the Finnish Foundation for Cardiovascular Research , the Yrjö Jahnsson Foundation , European Union 7th Framework Program (grant 201668 for AtheroRemo), EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition), and the Academy of Finland grant 322098 and Tampere University Hospital Supporting Foundation .
Funding Information:
We acknowledge Single Cell Genomics Core, Genome Center and Cell and Tissue Imaging Unit at University of Eastern Finland, Finnish Functional Genomics Centre, and Biocenter Finland for infrastructure support. This research has been conducted with the UK Biobank Resource (https://www.ukbiobank.ac.uk/) under application number 58990. We are grateful to Resolve Biosciences for their excellent service in optimizing and performing the Molecular Cartography experiments. This study was funded by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant no. 802825 to M.U.K.), Academy of Finland (grant no. 333021 and 335973 to M.U.K.; 311081 and 314557 to T. Lönnberg; 349708 to P.P.M.; 314556 and 335975 to A. Roivainen; 321535 and 328835 to J.P.L.), InFLAMES Flagship Programme of the Academy of Finland (337530 to T. Lönnberg), Finnish Foundation for Cardiovascular Research (M.U.K. P.R.M. and J.P.L.), Instrumentarium Science Foundation (P.R.M.), Ida Montinin Foundation (P.R.M.), Sigrid Jusélius Foundation (M.U.K.), GenomMed doctoral program (740264 to A. Ravindran), and Jane and Aatos Erkko Foundation (A. Roivainen). The Tampere Vascular Study (TVS) was supported with grants from the Competitive Research Funding of the Tampere University Hospital (grants 9M048 and 9N035 to T. Lehtimäki), the Emil Aaltonen Foundation (to T. Lehtimäki), the Pirkanmaa Regional Fund of the Finnish Cultural Foundation, the Research Foundation of Orion Corporation, the Jenny and Antti Wihuri Foundation, and the Academy of Finland (grants 322098 and 104821), the Finnish Foundation for Cardiovascular Research, the Yrjö Jahnsson Foundation, European Union 7th Framework Program (grant 201668 for AtheroRemo), EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition), and the Academy of Finland grant 322098 and Tampere University Hospital Supporting Foundation. The authors declare no competing interests.
Publisher Copyright:
© 2023 The Author(s)
PY - 2023/5
Y1 - 2023/5
N2 - Coronary artery disease (CAD) is a pandemic disease where up to half of the risk is explained by genetic factors. Advanced insights into the genetic basis of CAD require deeper understanding of the contributions of different cell types, molecular pathways, and genes to disease heritability. Here, we investigate the biological diversity of atherosclerosis-associated cell states and interrogate their contribution to the genetic risk of CAD by using single-cell and bulk RNA sequencing (RNA-seq) of mouse and human lesions. We identified 12 disease-associated cell states that we characterized further by gene set functional profiling, ligand-receptor prediction, and transcription factor inference. Importantly, Vcam1+ smooth muscle cell state genes contributed most to SNP-based heritability of CAD. In line with this, genetic variants near smooth muscle cell state genes and regulatory elements explained the largest fraction of CAD-risk variance between individuals. Using this information for variant prioritization, we derived a hybrid polygenic risk score (PRS) that demonstrated improved performance over a classical PRS. Our results provide insights into the biological mechanisms associated with CAD risk, which could make a promising contribution to precision medicine and tailored therapeutic interventions in the future.
AB - Coronary artery disease (CAD) is a pandemic disease where up to half of the risk is explained by genetic factors. Advanced insights into the genetic basis of CAD require deeper understanding of the contributions of different cell types, molecular pathways, and genes to disease heritability. Here, we investigate the biological diversity of atherosclerosis-associated cell states and interrogate their contribution to the genetic risk of CAD by using single-cell and bulk RNA sequencing (RNA-seq) of mouse and human lesions. We identified 12 disease-associated cell states that we characterized further by gene set functional profiling, ligand-receptor prediction, and transcription factor inference. Importantly, Vcam1+ smooth muscle cell state genes contributed most to SNP-based heritability of CAD. In line with this, genetic variants near smooth muscle cell state genes and regulatory elements explained the largest fraction of CAD-risk variance between individuals. Using this information for variant prioritization, we derived a hybrid polygenic risk score (PRS) that demonstrated improved performance over a classical PRS. Our results provide insights into the biological mechanisms associated with CAD risk, which could make a promising contribution to precision medicine and tailored therapeutic interventions in the future.
KW - atherosclerosis
KW - cell state
KW - coronary artery disease
KW - genetics
KW - genome-wide association study
KW - GWAS
KW - polygenic risk score
KW - scRNA-seq
KW - single cell
U2 - 10.1016/j.ajhg.2023.03.013
DO - 10.1016/j.ajhg.2023.03.013
M3 - Article
C2 - 37060905
AN - SCOPUS:85153608064
SN - 0002-9297
VL - 110
SP - 722
EP - 740
JO - AMERICAN JOURNAL OF HUMAN GENETICS
JF - AMERICAN JOURNAL OF HUMAN GENETICS
IS - 5
ER -